John H. McGee, PhD

Director and Scientific Co-Founder
Fog Pharmaceuticals, Massachusetts, United States

John McGee is a Scientific Co-Founder at FogPharma, where he leads the De Novo Discovery group. At Fog, he and and his team have developed a platform that combines ultra-high-throughput screening of phage libraries with multiplexed biochemical, biophysical, and cellular screening of synthetic libraries to rapidly discover and optimize helical binders to undruggable target proteins.

Disclosure information not submitted.

Presentation(s):

• Peptides and Small Proteins

  Tuesday, February 8, 2022
  1:00 PM – 2:30 PM

• Rapid Discovery of Helical Peptide Therapeutics Using Phage Display and Multiparameter Mass Spectrometry Screening

  Tuesday, February 8, 2022
  1:00 PM – 1:30 PM